Prader-Willi综合征儿童的生长激素治疗:青春期前儿童三年纵向数据及KIGS数据库中的成年身高数据
基于KIGS数据库1987至2012年全球回顾性队列数据,评估Prader-Willi综合征(PWS)儿童生长激素(GH)治疗的疗效与安全性。青春期前儿童522例治疗三年身高SDS改善至-0.31(1.34)(P<0.05),青春期组成年身高SDS为-1.19(1.37),总身高增幅0.95(1.32)SDS。安全性分析纳入2332例儿童,KIGS记录12例死亡报告。
要点
- 青春期前PWS儿童GH治疗三年身高SDS改善至-0.31(1.34)(P<0.05)。
- 青春期组成年身高SDS为-1.19(1.37),总身高增幅0.95(1.32)SDS。
- 青春期前组BMI SDS从1.11(2.09)升至1.53(1.43)(P<0.05),青春期组成年身高时BMI SDS为1.78(1.26)。
核心结论
- GH治疗显著改善PWS儿童的线性生长。
- BMI平均仍低于+2 SDS,与PWS自然病程中肥胖加重的趋势相反。
- 无论是否接受GH治疗,PWS儿童的安全性问题均应密切监测。
研究设计与样本
- 全球回顾性队列研究,数据来自KIGS数据库1987至2012年登记资料。
- 纳入522例接受GH治疗三年的青春期前儿童和173例达到成年身高的儿童。
- 安全性分析纳入2332例儿童。
主要发现
- 青春期前儿童三年GH治疗期间平均身高SDS改善至-0.31(1.34)(P<0.05)。
- 青春期组身高SDS改善至青春期开始时的-0.22(1.31)(P<0.05),但青春期期间丢失-0.77(0.81),最终平均成年身高SDS为-1.19(1.37)。
- 总身高增幅为0.95(1.32)SDS。
- 青春期前组BMI SDS从1.11(2.09)增至1.53(1.43)(P<0.05),青春期组无显著变化,成年身高时BMI SDS为1.78(1.26)。
- KIGS包含12例死亡报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Longitudinal data of children with Prader-Willi syndrome (PWS) treated with genotropin were registered in the Pfizer International Growth Database (KIGS). OBJECTIVE: To evaluate efficacy and safety of growth hormone (GH) treatment in a large group of children with PWS. DESIGN: Data registered in KIGS from 1987 to 2012. SETTING: Worldwide retrospective cohort study. PATIENTS: Patients included 522 prepubertal children treated with GH for three years and 173 children who had reached adult height. Safety analysis included 2332 children. Intervention involved GH treatment. MAIN OUTCOME MEASURE: Height standard deviation score (SDS), body mass index (BMI) SDS, occurrence of serious adverse events, and deaths reported in KIGS. RESULTS: In prepubertal children, mean (standard deviation) height SDS improved to -0.31 (1.34) (P < 0.05) during three years of GH treatment. In the adolescent group, height SDS improved until the start of puberty to -0.22 (1.31) (P < 0.05) but had a loss of -0.77 (0.81) during puberty, resulting in a mean adult height SDS of -1.19 (1.37). Total height gain was 0.95 (1.32) SDS. BMI SDS increased in the prepubertal group from 1.11 (2.09) to 1.53 (1.43) (P < 0.05) and did not significantly change in the adolescent group, who had a BMI SDS at an adult height of 1.78 (1.26). KIGS contained 12 death reports. CONCLUSIONS: GH treatment in children with PWS significantly improves linear growth. BMI remains on average below +2 SDS, in contrast to the natural course of increasing obesity in PWS. Safety should be closely monitored in children with PWS, with and without GH treatment.
引用
- Bakker NE, Lindberg A, Heissler J, et al. Growth Hormone Treatment in Children With Prader-Willi Syndrome: Three Years of Longitudinal Data in Prepubertal Children and Adult Height Data From the KIGS Database. J Clin Endocrinol Metab. 2017. PMID: 28323917. doi:10.1210/jc.2016-2962
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。